CL2023000216A1 - Anticuerpos anti-abeta - Google Patents

Anticuerpos anti-abeta

Info

Publication number
CL2023000216A1
CL2023000216A1 CL2023000216A CL2023000216A CL2023000216A1 CL 2023000216 A1 CL2023000216 A1 CL 2023000216A1 CL 2023000216 A CL2023000216 A CL 2023000216A CL 2023000216 A CL2023000216 A CL 2023000216A CL 2023000216 A1 CL2023000216 A1 CL 2023000216A1
Authority
CL
Chile
Prior art keywords
antibodies
abeta antibodies
methods
abeta
bind
Prior art date
Application number
CL2023000216A
Other languages
English (en)
Inventor
Barbour Robin
Zago Wagner
S Nijjar Tarlochan
Skov Michael
Govindarajan Sridhar
Purcell Tom
Welch Mark
Bard Frédérique
Original Assignee
Othair Prothena Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Othair Prothena Ltd filed Critical Othair Prothena Ltd
Publication of CL2023000216A1 publication Critical patent/CL2023000216A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos que se unen al péptido beta-amiloide humano, métodos para detectar, medir y tratar trastornos amiloidogénicos con dichos anticuerpos, composiciones farmacéuticas que comprenden los anticuerpos y métodos de elaboración.
CL2023000216A 2020-07-23 2023-01-23 Anticuerpos anti-abeta CL2023000216A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063055813P 2020-07-23 2020-07-23
US202063086589P 2020-10-01 2020-10-01
US202163187379P 2021-05-11 2021-05-11
US202163219611P 2021-07-08 2021-07-08

Publications (1)

Publication Number Publication Date
CL2023000216A1 true CL2023000216A1 (es) 2023-10-20

Family

ID=79728984

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023000216A CL2023000216A1 (es) 2020-07-23 2023-01-23 Anticuerpos anti-abeta
CL2024000953A CL2024000953A1 (es) 2020-07-23 2024-04-01 Anticuerpos anti-abeta

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024000953A CL2024000953A1 (es) 2020-07-23 2024-04-01 Anticuerpos anti-abeta

Country Status (14)

Country Link
US (7) US20220049009A1 (es)
EP (1) EP4185612A1 (es)
JP (1) JP2023535024A (es)
KR (1) KR20230039734A (es)
CN (1) CN116348487A (es)
AU (1) AU2021310926A1 (es)
BR (1) BR112023001061A2 (es)
CA (1) CA3186614A1 (es)
CL (2) CL2023000216A1 (es)
IL (1) IL300059A (es)
MX (1) MX2023000949A (es)
TW (1) TW202216760A (es)
UY (1) UY39337A (es)
WO (1) WO2022020680A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023001061A2 (pt) * 2020-07-23 2023-04-04 Othair Prothena Ltd Anticorpos antiabeta
US12084492B2 (en) 2023-01-20 2024-09-10 Mabwell Therapeutics, Inc. Anti-amyloid beta protofibril/oligomer antibodies and uses thereof
WO2024157085A1 (en) * 2023-01-26 2024-08-02 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003097A (en) 1958-07-17 1961-10-03 Gen Electric Sequence control system for timing motor
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6518011B1 (en) 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
US7629311B2 (en) 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
CZ2008595A3 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE60230736D1 (de) 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
US20050129695A1 (en) 2003-03-28 2005-06-16 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP2434420A3 (en) 2003-08-01 2012-07-25 Dna Twopointo Inc. Systems and methods for biopolymer engineering
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
CN101027391A (zh) 2004-10-05 2007-08-29 惠氏公司 用于改善重组蛋白质产生的方法和组合物
EP1814917A2 (en) 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
CA2589017A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EA201100177A1 (ru) 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
PT1960428E (pt) 2005-12-12 2011-10-07 Hoffmann La Roche Anticorpos glicosilados na região variável contra beta-amilóide 4
CN103539857A (zh) 2006-03-30 2014-01-29 葛兰素集团有限公司 针对β-淀粉样蛋白肽的抗体
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
WO2008030251A1 (en) 2006-09-08 2008-03-13 Georgetown University Deglycosylated anti-amyloid beta antibodies
BRPI0719763A2 (pt) 2006-10-02 2014-01-28 Ac Immune Sa Anticorpo, molécula de ácido nucleico, vetor de expressão, célula, composição, mistura, uso de um anticorpo quimérico ou um fragmento do mesmo ou um anticorpo humanizado ou um fragmento do mesmo e/ou uma parte funcional e/ou uma composição farmacêutica ou uma mistura, métodos para a preparação de uma composição farmacêutica ou de uma mistura, para prevenir, tratar ou aliviar os efeitos de uma doença, de diagnóstico de uma doença ou condição associada com amilóide em um paciente e de determinação do grau da carga de placa amiloidogênica em um tecido e/ou fluidos corporais, kits de teste para a detecção e diagnóstico de doenças e condições associadas com amilóide, região variável de cadeia leve, região variável de cadeia pesada, linhagem de célula, gene de anticorpo, e, métodos para desagregar fibras de beta-amilóide pré formadas, para prevenir a degradação de neurônio induzida por abeta, para diagnosticar uma predisposição a uma doença ou condição associada com amilóide em um paciente, para monitorar doença residual mínima em um paciente, para prognosticar a responsividade de um paciente que é tratado com um anticorpo ou uma composição de vacina, para reduzir a carga de placa no cérebro de um animal, para reduzir a quantidade de placas no cérebro de um animal, para diminuir a quantidade total de abeta solúvel no cérebro de um animal e para reter ou aumentar a capacidade de memória cognitiva em um mamífero.
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2011526240A (ja) 2007-04-18 2011-10-06 ヤンセン アルツハイマー イミュノセラピー 脳アミロイド血管症の予防および治療
PE20090766A1 (es) 2007-06-12 2009-07-09 Ac Immune Sa Anticuerpo igg1 humanizado
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
SG178809A1 (en) 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US20100291071A1 (en) 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
AU2009269700B2 (en) 2008-07-09 2015-07-16 University Of Zurich Method of promoting neurogenesis
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DK2419447T3 (en) 2009-04-17 2017-09-25 Immunas Pharma Inc ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
US8512677B2 (en) 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
BRPI1012195A2 (pt) 2009-05-01 2018-04-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
US8617549B2 (en) 2009-09-11 2013-12-31 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
TW201144437A (en) 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9910049B2 (en) 2014-09-11 2018-03-06 Amprion, Inc. Detection of misfolded amyloid beta protein
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
RS54685B1 (en) 2010-08-12 2016-08-31 Eli Lilly And Company ANTI-N3pGlu AMILOID BETA PEPTID ANTIBODIES AND THEIR USES
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2013082045A1 (en) 2011-11-28 2013-06-06 Buck Institute For Age Research Netrin loop peptide mimetics and uses thereof
EP2807188B1 (en) * 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2014007982A2 (en) 2012-07-03 2014-01-09 Janssen Alzheimer Immunotherapy C-terminal and central epitope a-beta antibodies
JP2016501247A (ja) 2012-12-07 2016-01-18 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー 抗Ａβ抗体を使用して脳アミロイド斑を減少させる方法
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
US9486559B2 (en) 2013-05-07 2016-11-08 Abbott Cardiovascular Systems Inc. Methods of treatment with a bioresorbable scaffold for neurologic drug delivery
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015035190A1 (en) 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
DK3083681T3 (da) * 2013-12-20 2020-08-24 Neurimmune Holding Ag Antistofbaseret terapi af transthyretin- (ttr) amyloidose og human-afledte antistoffer dertil
CA2938731A1 (en) 2014-02-08 2015-08-13 Genentech, Inc. Methods of treating alzheimer's disease
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
US20170152306A1 (en) 2014-05-16 2017-06-01 Universitat Autonoma De Barcelona Single chain variable fragment (scfv) elongation mutants
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
WO2016016278A2 (en) 2014-07-29 2016-02-04 Neurimmune Holding Ag Human-derived anti-huntingtin (htt) antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
US10494425B2 (en) 2015-02-24 2019-12-03 Rpeptide, Llc Anti-amyloid-beta antibodies
NZ739181A (en) 2015-07-16 2023-05-26 Vivoryon Therapeutics N V Anti-pyroglutamated amyloid beta humanized antibodies
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
CN108602883A (zh) 2016-01-20 2018-09-28 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
US11340225B2 (en) 2016-03-14 2022-05-24 Biogen International Neuroscience Gmbh Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
IL263433B2 (en) 2016-06-07 2024-03-01 Biogen Int Neuroscience Gmbh Methods for treating Alzheimer's disease
AU2017299579A1 (en) 2016-07-19 2019-01-24 Annexon, Inc. Compositions and methods for treating frontotemporal dementia
US20200299411A9 (en) 2016-10-27 2020-09-24 Eisai R&D Management Co., Ltd. Composition and method for treating alzheimer's disease
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
CA3043651A1 (en) 2016-11-15 2018-05-24 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
WO2018119001A1 (en) 2016-12-19 2018-06-28 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
WO2018204408A1 (en) 2017-05-02 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Methods of diagnosing and treating alzheimer's disease
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
PT3672631T (pt) 2017-08-22 2023-05-23 Biogen Ma Inc Composições farmacêuticas contendo anticorpos anti-betaamiloide
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
WO2019074840A1 (en) 2017-10-09 2019-04-18 Keith Black COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
JP7387613B2 (ja) 2018-02-09 2023-11-28 ザ トラスティーズ オブ ダートマス カレッジ 神経変性疾患及び障害の治療のためのキメラ抗原受容体
MX2021000235A (es) 2018-07-17 2021-03-25 Jiangsu Hengrui Medicine Co Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo.
EP3826674A2 (en) 2018-07-24 2021-06-02 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
WO2020037258A1 (en) 2018-08-17 2020-02-20 Ab Studio Inc. Catabodies and methods of use thereof
JP7499760B2 (ja) 2018-11-02 2024-06-14 アネクソン，インコーポレーテッド 脳損傷を治療するための組成物及び方法
US20220213223A1 (en) 2019-02-12 2022-07-07 Prothena Biosciences Limited Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
CR20210492A (es) 2019-03-26 2021-11-19 Janssen Pharmaceutica Nv ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
EP4010367A4 (en) 2019-04-04 2023-10-11 The Royal Institution for the Advancement of Learning / McGill University USE OF ASS34 TO EVALUATE ALZHEIMER'S DISEASE
WO2020257745A1 (en) 2019-06-21 2020-12-24 University Of Kansas Compositions and methods useful in treating brain diseases
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
US20230027014A1 (en) 2019-11-12 2023-01-26 Ambetex Pty Ltd Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction
US20230183328A1 (en) 2020-03-20 2023-06-15 Eisai R&D Management Co., Ltd. HIGH CONCENTRATION ANTI-Abeta PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF
BR112023001061A2 (pt) 2020-07-23 2023-04-04 Othair Prothena Ltd Anticorpos antiabeta

Also Published As

Publication number Publication date
IL300059A (en) 2023-03-01
US20220041701A1 (en) 2022-02-10
EP4185612A1 (en) 2023-05-31
UY39337A (es) 2022-02-25
JP2023535024A (ja) 2023-08-15
TW202216760A (zh) 2022-05-01
US20220089762A1 (en) 2022-03-24
CL2024000953A1 (es) 2024-07-26
MX2023000949A (es) 2023-02-22
WO2022020680A1 (en) 2022-01-27
AU2021310926A1 (en) 2023-03-23
US20220242940A1 (en) 2022-08-04
US11440953B2 (en) 2022-09-13
US20220041699A1 (en) 2022-02-10
CN116348487A (zh) 2023-06-27
US11434285B2 (en) 2022-09-06
US20230331828A1 (en) 2023-10-19
CA3186614A1 (en) 2022-01-27
US11434283B2 (en) 2022-09-06
BR112023001061A2 (pt) 2023-04-04
KR20230039734A (ko) 2023-03-21
US20220049009A1 (en) 2022-02-17
US11434284B2 (en) 2022-09-06
US20220041700A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CL2023000216A1 (es) Anticuerpos anti-abeta
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
CL2020001003A1 (es) Anticuerpos anti-tau y uso de los mismos.
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CO2021016907A2 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112019010034A2 (pt) fator viii alvejado de hemácia e método de uso do mesmo
EA202190633A1 (ru) Лекарственные формы для применения в педиатрии, способы получения и применения
CO2023013500A2 (es) Anticuerpos anti-cd19 y estructuras car-t
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo